Soliris access in Saudi Arabia

Quick orientation

Soliris is the brand name for eculizumab, a humanized monoclonal antibody that binds terminal complement protein C5 and blocks its cleavage into C5a and C5b. It is approved by the FDA for four indications: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive, and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). The Saudi Food and Drug Authority (SFDA) has registered Soliris in the Kingdom through local agent arrangements, primarily for PNH and aHUS. The access conversation has three defining elements: meningococcal vaccination is a hard prerequisite of the US prescribing standard (REMS), the infusion site (not the patient's home) is the delivery endpoint, and Ultomiris (ravulizumab) is the often-preferred therapy in markets where it is available. Reserve Meds coordinates the US-side sourcing, validated 2 to 8 degrees Celsius cold-chain logistics, and the handshake with the receiving infusion center. Reserved for you.

Why patients in Saudi Arabia need Soliris via NPP

PNH and aHUS are rare complement-mediated disorders. gMG and NMOSD are rare neurologic diseases driven by autoantibody-mediated injury that complement potentiates. In Saudi Arabia, SFDA has registered Soliris primarily for PNH and aHUS, with availability through tertiary hospitals and specialty infusion centers. Several friction points surface for Saudi patients even with that registration in place.

First, stocking concentrates at one or two tertiary centers, and patients living outside the catchment areas (Riyadh, Jeddah, and select Eastern Province sites) cannot always access continuous supply through their local pharmacy network. Second, the gMG and NMOSD indications may not have been added to the local label even where PNH and aHUS are registered, which leaves patients with those FDA-on-label diagnoses in an off-label-in-country situation. Third, Soliris is a chronic, indefinite therapy and the every-14-days maintenance cadence requires sustained operational continuity that does not always align with stocking patterns. Fourth, cost. Even where Soliris is technically available, the absence of national payer coverage for terminal complement inhibitors at this price point forces a cash-pay procurement pathway for many families.

The PIP framework supports the patient-specific filing where stocking gaps, off-label-in-country indication framing, or supply continuity questions arise.

The SFDA Personal Importation Program for Soliris

The SFDA Personal Importation Program (PIP) allows a Saudi-licensed physician to request import of a specific medicine for a specific named patient when local stocking does not match the patient's clinical need. For Soliris, the PIP filing covers the patient's full induction-and-maintenance course, with dose-by-dose tracking against the indication-specific schedule.

The application package contains a clinical justification letter from the treating specialist (hematology for PNH, nephrology or hematology for aHUS, neurology for gMG or NMOSD), addressing diagnosis with ICD-10 coding, antibody-status documentation (AChR antibody positivity for gMG, AQP4 antibody positivity for NMOSD, ADAMTS13 and complement assays for aHUS as appropriate, intravascular hemolysis evidence with elevated LDH for PNH), disease severity, prior therapies attempted with outcomes, why a terminal complement inhibitor is clinically appropriate, and the proposed dosing plan.

The clinical-justification angle that distinguishes Soliris from most other named-patient filings is the meningococcal vaccination documentation. The US REMS program requires that meningococcal vaccination against serogroups A, C, W, Y, and B be completed at least two weeks before the first dose. This US regulatory infrastructure does not transfer into the destination country, but the receiving Saudi specialist operates under local pharmacovigilance rules with the same clinical standard. Reserve Meds documents the patient's vaccination status as part of intake even when local prescribing rules differ. The dispensing facility license confirmation (the receiving infusion center holds an SFDA pharmacy license and the operational infrastructure for IV biologic infusion with cold-chain storage) is the second pillar of the application.

Approval timelines for routine cases at major institutions run 10 to 21 business days. First-time complex cases (NMOSD with the indication not on the local label, or aHUS with weight-banded pediatric dosing across multiple body weight tiers) can extend to 6 to 10 weeks. SFDA does not publish guaranteed turnaround times.

Where Soliris gets dispensed in Saudi Arabia

The treating-center map for Soliris concentrates at tertiary institutions with the relevant specialty programs and IV biologic infusion capability. King Faisal Specialist Hospital and Research Centre (KFSH&RC) carries hematology, nephrology, neurology, and the bone marrow and renal transplant programs that often surface PNH and aHUS cases. King Abdulaziz Medical City (KAMC) and the Ministry of National Guard Health Affairs (MNGHA) network operate strong adult and pediatric specialty programs. King Saud University Medical City (KSUMC) carries academic specialty capacity.

Major private networks (Dr. Sulaiman Al Habib Medical Group, Saudi German Health, Dr. Soliman Fakeeh Hospital, Dallah Hospital) carry IV infusion capability with refrigerated storage and have established import pharmacy workflows. The receiving facility, not the patient's home, is the delivery endpoint. The 30 mL single-use vials at 10 mg/mL must be stored refrigerated at 2 to 8 degrees Celsius in the original carton, protected from light, and infused over approximately 35 minutes in adults (longer in pediatric patients) after dilution to 5 mg/mL in a compatible IV solution.

Real cost picture for Soliris in Saudi Arabia

Vial-level US wholesale acquisition cost (WAC) is commonly cited at approximately USD 7,000 per 300 mg vial. At the SAR 3.75 peg, that converts to approximately SAR 26,250 per vial. Annual US WAC for PNH dosing in an average-weight adult is in the range of USD 500,000 to USD 700,000 (SAR 1.88 million to SAR 2.63 million); aHUS, gMG, and NMOSD maintenance dosing lands at the higher end because of the larger 1,200 mg maintenance dose.

International logistics for the cold-chain shipment from the validated US wholesaler to the receiving Saudi infusion center add a defined surcharge in the SAR 3,000 to SAR 9,400 range (USD 800 to USD 2,500) per shipment for refrigerated air freight with continuous temperature monitoring, customs pre-clearance to avoid tarmac temperature excursions, and the hand-off SOP to the receiving infusion facility. The Reserve Meds concierge coordination fee is a separate line item.

Local insurer behavior varies by indication. Bupa Arabia, Tawuniya, and MedGulf may reimburse PNH and aHUS under managed-entry frameworks where the diagnosis is documented and the patient meets clinical criteria. gMG and NMOSD coverage at the Soliris price point is less consistent. Cash-pay is the default operating posture for cross-border-coordinated cases. The 2024 to 2025 US launch of eculizumab biosimilars (EPYSQLI / eculizumab-aagh, Bkemv) at roughly a 30 percent discount to Soliris WAC introduces meaningful domestic price pressure but does not change the international NPP picture in jurisdictions where biosimilars are not yet registered.

Typical timeline for Soliris in Saudi Arabia

The SFDA regulatory layer for a routine Soliris filing at a major institution runs 10 to 21 business days; first-time complex cases extend to 6 to 10 weeks. The clinical loading-and-maintenance schedule depends on the indication. Adult PNH dosing is 600 mg IV every 7 days for 4 weeks, then 900 mg IV at week 5, then 900 mg IV every 14 days indefinitely. Adult aHUS, gMG, and NMOSD dosing is 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 14 days. Reserve Meds pre-stages cold-chain shipments against the every-14-days maintenance cadence as continuing-care coordination.

What your physician needs to provide

The clinical justification letter, signed by a treating specialist holding an active SCFHS license, addresses diagnosis with ICD-10 coding, antibody-status documentation appropriate to the indication, disease severity (intravascular hemolysis evidence with elevated LDH for PNH; thrombotic microangiopathy with thrombocytopenia and acute kidney injury for aHUS; AChR-antibody-positive symptomatic gMG; AQP4-antibody-positive NMOSD with relapsing course), prior therapies attempted with outcomes, the dosing plan per indication, and the monitoring plan.

The dosing reference follows the FDA label by indication. Adult PNH: 600 mg IV every 7 days for 4 weeks (4 doses), then 900 mg IV at week 5, then 900 mg IV every 14 days as ongoing maintenance. Adult aHUS at or above 40 kg: 900 mg IV every 7 days for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 14 days. Pediatric aHUS dosing is fully weight-banded across multiple body weight tiers per the package insert. Adult gMG and NMOSD: 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 14 days.

The monitoring plan covers LDH and reticulocyte count in PNH; platelet count, serum creatinine, and LDH in aHUS; clinical symptom monitoring in gMG and NMOSD; and infection vigilance across all indications. The meningococcal vaccination documentation (serogroups A, C, W, Y, and B at least two weeks before first dose, with revaccination per ACIP recommendations) is a discrete element of the file. The dominant safety concern is serious meningococcal infection due to terminal complement blockade; the receiving infusion center's clinical and pharmacy team must be aware of this risk and the warning signs in every patient on therapy.

Common questions about Soliris in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Soliris? Coverage varies by indication. PNH and aHUS are more commonly reimbursed under managed-entry frameworks where diagnosis is documented and clinical criteria are met. gMG and NMOSD coverage at the Soliris price point is less consistent. Pre-authorization with the clinical justification letter attached is common. Cash-pay is the default operating posture for cross-border-coordinated cases.

Why is meningococcal vaccination mandatory? Eculizumab blocks terminal complement, which protects against encapsulated organisms including Neisseria meningitidis. Meningococcal infections have been reported in both vaccinated and unvaccinated patients on the drug. The US REMS program requires vaccination at least two weeks before the first dose. Reserve Meds documents vaccination status as part of intake. The receiving Saudi prescriber operates under local pharmacovigilance rules with the same clinical standard.

Why Soliris versus Ultomiris? Ultomiris (ravulizumab) is the longer-acting C5 inhibitor from the same manufacturer, dosed every 8 weeks in maintenance rather than every 2 weeks. In many markets, Ultomiris has become the preferred long-term therapy where the payer pathway supports it. Soliris remains in active use where Ultomiris is not yet registered or reimbursed locally, or where the treating clinician has clinical reasons to continue eculizumab specifically. The Reserve Meds patient onboarding conversation includes a clinical-context note confirming the treating physician's specific decision to continue eculizumab rather than transition.

What about Iptacopan (Fabhalta) or Pegcetacoplan (Empaveli) for PNH? Iptacopan is an oral factor B inhibitor approved for PNH in 2023. Pegcetacoplan is a C3 inhibitor approved for PNH. Both are alternatives in the PNH treatment landscape and are part of the clinical conversation between patient and treating hematologist.

What is the dispensing setting? The receiving infusion center, not the patient's home. The dilution-to-infusion stability window is up to 24 hours under refrigeration or room temperature per the label, and the IV infusion runs approximately 35 minutes in adults. Reserve Meds confirms a receiving infusion center is in place before procurement.

Is this a chronic therapy? Yes. Soliris is not curative. Treatment continues indefinitely. Discontinuation in PNH and aHUS carries a documented risk of severe hemolysis or thrombotic microangiopathy rebound; patients planning a treatment pause require monitoring per the FDA label warnings.

Where Reserve Meds fits in Soliris cases

Reserve Meds is a US-based concierge coordinator. For a Soliris inquiry from a Saudi patient, the working unit is confirmed receiving infusion center in the destination country before procurement, US-side sourcing through validated wholesaler channels, validated 2 to 8 degrees Celsius cold-chain shippers with continuous temperature monitoring, customs pre-clearance, and the handshake with the receiving infusion facility for unbroken cold chain on arrival. The clinical decisions remain with the treating specialist. The regulatory authority remains SFDA. The dispensing remains with the licensed Saudi infusion center.

What Reserve Meds carries: preparation of the documentation kit including the meningococcal vaccination documentation, the indication-specific clinical justification reference, and the SFDA pharmacovigilance reference; validated cold-chain logistics with lane-tested transit routes; the every-14-days maintenance cadence pre-staged against the institutional infusion schedule; and a single named coordinator who stays with the patient across the chronic, indefinite treatment arc. Because Ultomiris is the often-preferred therapy in markets where it is available, the patient onboarding conversation includes a clinical-context note confirming the treating physician's specific decision to continue eculizumab. Reserved for you.

Next step

If you or a family member are considering Soliris in Saudi Arabia for PNH, aHUS, generalized myasthenia gravis, or NMOSD, the first step is a coordinated intake that confirms eligibility, infusion-center fit, and a transparent firm quote. The waitlist request prefills the relevant context so the coordinator who reaches out is already oriented to your case.

Join the Soliris waitlist

Reserved for you.